629655-20-5

Upstream product

• 449758-31-0 5-Chloro-2-(1H-1,2,4-triazol-1-yl)benzonitrile 
• 21663-61-6 2,5-dichlorobenzonitrile 
• 629655-19-2 5-chloro-2-(1H-1,2,4-triazol-1-yl)benzoic acid 
• 404922-74-3 [5-chloro-2-(1H-1,2,4-triazol-1-yl)phenyl]methanol 
• 404922-80-1 1-[2-(bromomethyl)-4-chlorophenyl]-1H-1,2,4-triazole 
• 143-33-9 sodium cyanide 

Downstream Products

• 629655-21-6 2-(1,2,4-triazol-1-yl)-5-chlorophenylacetic acid 
• 629655-39-6 tert-butyl 2-[2-({2-[5-chloro-2-(1H-1,2,4-triazol-1-yl)benzyl][1,3]oxazolo[4,5-c]pyridin-4-yl}amino)ethyl]piperidine-1-carboxylate 
• 629655-38-5 tert-butyl 2-(2-{[3-({[5-chloro-2-(1H-1,2,4-triazol-1-yl)phenyl]acetyl}amino)-4-hydroxypyridin-2-yl]amino}ethyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization

Thrombin-inhibitor X-ray crystal structures, in combination with the installation of binding elements optimized within the pyrazinone series of thrombin inhibitors, were utilized to transform a weak triazolopyrimidine lead into a series of potent oxazolop

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof.